BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30559256)

  • 1. NF-κB and Poly (ADP-ribose) Polymerase 1 Form a Positive Feedback Loop that Regulates DNA Repair in Acute Myeloid Leukemia Cells.
    Li D; Luo Y; Chen X; Zhang L; Wang T; Zhuang Y; Fan Y; Xu J; Chen Y; Wu L
    Mol Cancer Res; 2019 Mar; 17(3):761-772. PubMed ID: 30559256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the novel LincRNA uc002jit.1 in NF-kB-mediated DNA damage repair in acute myeloid leukemia cells.
    Li D; Yu Z; Wang T; Li Y; Chen X; Wu L
    Exp Cell Res; 2020 Jun; 391(2):111985. PubMed ID: 32259522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation.
    Faraoni I; Aloisio F; De Gabrieli A; Consalvo MI; Lavorgna S; Voso MT; Lo-Coco F; Graziani G
    Cancer Lett; 2018 Jun; 423():127-138. PubMed ID: 29526802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of PARP1 regulation in radiation-induced rescue effect.
    Pathikonda S; Cheng SH; Yu KN
    J Radiat Res; 2020 May; 61(3):352-367. PubMed ID: 32329510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
    Jin Y; Lu Z; Ding K; Li J; Du X; Chen C; Sun X; Wu Y; Zhou J; Pan J
    Cancer Res; 2010 Mar; 70(6):2516-27. PubMed ID: 20215516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
    Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F
    Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
    Zhang L; Li DQ
    Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
    Tian S; Lou L; Tian M; Lu G; Tian J; Chen X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):143. PubMed ID: 32711558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
    Muvarak NE; Chowdhury K; Xia L; Robert C; Choi EY; Cai Y; Bellani M; Zou Y; Singh ZN; Duong VH; Rutherford T; Nagaria P; Bentzen SM; Seidman MM; Baer MR; Lapidus RG; Baylin SB; Rassool FV
    Cancer Cell; 2016 Oct; 30(4):637-650. PubMed ID: 27728808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rapid fluorescent method for the real-time measurement of poly(ADP-ribose) polymerase 1 activity.
    Kurgina TA; Anarbaev RO; Sukhanova MV; Lavrik OI
    Anal Biochem; 2018 Mar; 545():91-97. PubMed ID: 29326071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
    Han S; Brenner JC; Sabolch A; Jackson W; Speers C; Wilder-Romans K; Knudsen KE; Lawrence TS; Chinnaiyan AM; Feng FY
    Neoplasia; 2013 Oct; 15(10):1207-17. PubMed ID: 24204199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of NF-kappaB signaling and PARP1 activity in the TNF-induced inhibition of PHEX gene expression in human osteoblasts.
    Kędzierska U; Banasiak Ł; Kiela P; Majewski PM
    Acta Biochim Pol; 2018 Nov; 65(4):573-571. PubMed ID: 30440055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer.
    Tang L; Wang M; Jiang L; Zeng C
    Hum Cell; 2020 Jul; 33(3):801-809. PubMed ID: 32388810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
    Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
    Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of the NF-κB signalling pathway and the DNA repair gene PARP1 in predicting distant metastasis after breast cancer surgery.
    Pan K; Li X; He J; Lei Y; Yang Y; Jiang D; Tang Y
    Sci Rep; 2024 Feb; 14(1):4402. PubMed ID: 38388665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP1-LSD1 functional interplay controls transcription of SOD2 that protects human pro-inflammatory macrophages from death under an oxidative condition.
    Tokarz P; Płoszaj T; Regdon Z; Virág L; Robaszkiewicz A
    Free Radic Biol Med; 2019 Feb; 131():218-224. PubMed ID: 30529301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors.
    Wang C; Tang H; Geng A; Dai B; Zhang H; Sun X; Chen Y; Qiao Z; Zhu H; Yang J; Chen J; He Q; Qin N; Xie J; Tan R; Wan X; Gao S; Jiang Y; Sun FL; Mao Z
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26356-26365. PubMed ID: 33020270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
    Tempka D; Tokarz P; Chmielewska K; Kluska M; Pietrzak J; Rygielska Ż; Virág L; Robaszkiewicz A
    Redox Biol; 2018 May; 15():316-326. PubMed ID: 29306194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.